Urogen Pharma (URGN)
(Real Time Quote from BATS)
$13.30 USD
-0.25 (-1.85%)
Updated May 31, 2024 03:46 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Urogen Pharma [URGN]
Reports for Purchase
Showing records 41 - 48 ( 48 total )
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
FerGene Spinout Underscores Bladder Cancer Market Potential; 3Q19 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Stock Price Attrition Appears Overdone; Approaching Critical Value Inflection Points; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; UGN-101 Regulatory Filing Approaches; UGN-102 Data Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
OLYMPUS Trial Follow-Up Data Reveal Long-Term Treatment Responses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Urothelial Carcinoma Expert Conference Call Recap Note
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Positive Expert Physician Comments Underscore Pipeline Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Spending Higher Than Projected; Reiterate Buy and Modulating Price Target to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
A Next-Generation Leader in Urology; Initiating at Buy and $82 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R